HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Q2

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble CEO A.G. Lafley highlights consumer products giant's interest "in biotechnology and nanotechnology" during Jan. 27 second quarter sales and earnings call. "They're both potentially transformative technologies," exec says, adding, "We are committed to innovation and innovation leadership, but we are in very early stages" of development in those areas. Reported net sales in Q2 including Gillette increased 27% to $18.3 bil. and net income was up 29% to $2.55 bil. Beauty care revenues were up 7% to $5.37 bil., including a negative 2% foreign exchange impact, and net earnings in the segment advanced 7% to $848 mil. Skin care generated double-digit volume growth on products like Olay Renegerist and Total Effects Cleansing, according to the company. Health Care net sales grew 29% to $2.64 bil., driven by the addition of Gillette oral care, and net earnings were $27 mil., up 41%. Gillette blades and razors sales for the quarter grew 6% to $1.15 bil. on M3Power, Venus Vibrance and disposables, versus pro forma results released Oct. 4, 2005. Reported net earnings before income and taxes rose 11% to $375 mil. versus pro forma results. P&G predicts net sales in FY 2006 will increase 18%-20%, company adds...

You may also be interested in...



Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.

Unfairly Hit By Influencer Assassins? Now Could Be Your Chance To Mobilize The FTC

Brands unfairly attacked by powerful influencers could raise the subject with the US Federal Trade Commission, which is asking for comments on its “Endorsement Guides."  

UsernamePublicRestriction

Register

RS013676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel